×
About 83,978 results

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
https://clinicaltrials.gov/ct2/show/NCT03412565

Jul 15th, 2022 - The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected...

Brief Intervention for OCD Fears
https://clinicaltrials.gov/ct2/show/NCT02790710

Aug 5th, 2022 - Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear reactivation procedure. Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral avoidance task 2 weeks after the ...

Mirtazapine Versus Dexamethasone in Preventing Postoperative Nausea and Vomiting
https://clinicaltrials.gov/ct2/show/NCT04547842

Aug 5th, 2022 - this double-blinded randomized study will be conducted at Ain-Shams university hospitals. Patients are aged 21-60 years and body weight 60-100 Kg of the American Society of Anaesthesiologists (ASA) physical status I or II scheduled for laparoscopic cholecystectomy under general anesthesia will be enrolled in this study., patients will be randomly divided into 2 equal groups; The M(Mirtazapine) ...

Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s
https://clinicaltrials.gov/ct2/show/NCT04488263

Aug 5th, 2022 - Background: Neuroendocrine neoplasm (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring for example in the gastrointestinal tract, islets of the pancreas, lung, adrenal medulla, thyroid C-cells, etc. and are heterogeneous group of neoplasms with unique tumor biology, natural history, and clinical management issues. The...

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03532217

Aug 5th, 2022 - This study study aims to elucidate the immune responses to a shared antigen vaccine (PROSTVAC) and tumor specific antigens generated DNA vaccine in combination with checkpoint blockade using nivolumab (anti-PD-1), and ipilimumab (anti-CTLA-4). Additionally, the investigators will study the impact of the combination immunotherapy on peripheral T cell activation, as well as immune response in the...

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02688140

Aug 5th, 2022 - Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification APL is designated as"M3 leukemia" and assigned to the WHO defined type of AML with recurrent cytogenetic abnormalities, "acute promyelocytic leukemia with t(15;17)(q22;q12), (PML/RARα) and variants". Des...

Endometrial Basis for Infertility in Women With Recurrent Implantation Failure and Pregnancy Loss
https://clinicaltrials.gov/ct2/show/NCT04939064

Aug 5th, 2022 - Pregnancy loss is the most common complication of human gestation, occurring in roughly one-half of natural conceptions and most frequently in the first two to three weeks of gestation. In recent years it has become apparent that constitutive endometrial dysfunction represents an important contributor to infertility in women being treated with assisted reproductive technologies (ART). This appl...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Aug 5th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of progression to MM of 72-75% in 5 years with median time to progression of <2 years. The current standard of care for SMM is close follow-up without t...

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
https://clinicaltrials.gov/ct2/show/NCT03834883

Aug 5th, 2022 - Torsades de pointes (TdP) is a catastrophic arrhythmia associated with corrected QT (QTc) interval prolongation, which can be induced by > 150 commonly prescribed drugs. TdP risk is higher in women and is modulated by the ratio of serum progesterone and estradiol; the higher the serum progesterone and progesterone:estradiol ratio, the lower the risk, and vice-versa. TdP risk increases with age,...

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
https://clinicaltrials.gov/ct2/show/NCT03918278

Aug 5th, 2022 - This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors for which there is no available therapy which may convey clinical benefit. Part 2 is expansion cohort to d...

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT04869943

Aug 5th, 2022 - This study is a multicenter, randomized, open-label, two treatment arm, efficacy and safety study. Subjects will be randomized to the two treatment arms in a 1:1 fashion. The primary efficacy endpoint of the study will be the median rPFS. Subjects will continue study treatment until disease progression is observed or an unacceptable adverse event is observed. A safety follow up visit will occur...

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans
https://clinicaltrials.gov/ct2/show/NCT04920539

Aug 5th, 2022 - In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes. To test these hypotheses, the investigators propose defining the epigenomic and transcriptomic alterations at single cell resolutio...

Lumbar Erector Spinae Plane Block for Back Surgery
https://clinicaltrials.gov/ct2/show/NCT03825198

Aug 5th, 2022 - In this prospective randomized double blind placebo controlled clinical trial we would like to assess the efficacy of a bilateral lumbar erector spinae block on the 24h morphine consumption after posterior lumbar interbody fusion surgery. Patients scheduled for 1-2 level PLIF surgery will be recruited in AZ KLINA in Brasschaat and the University Hospital Antwerp in Edegem. The study contains tw...

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
https://clinicaltrials.gov/ct2/show/NCT04060394

Aug 5th, 2022 - The Phase I part of this study will perform a dose-escalation to identify the recommended Phase II dose of LAE001/prednisone plus afuresertib in m-CRPC patients. In the Phase II part of this study, the anti-tumor efficacy of LAE001/prednisone plus afuresertib and docetaxel/prednisone plus afuresertib will be assessed in mCRPC patients with PTEN loss and/or PIK3CA/AKT/PTEN alteration who have pr...

Dexmedetomidine Compared to Ketofol for Sedation in Paediatrics
https://clinicaltrials.gov/ct2/show/NCT04678050

Aug 5th, 2022 - This double-blind, parallel-group, randomized clinical study will recruiter anxious children who will undergo dental pulp therapy. The study participants will be allocated into two equal groups. Subjects in group I will receive ketofol solution (ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously ...

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
https://clinicaltrials.gov/ct2/show/NCT04675788

Aug 5th, 2022 - Torsades de pointes (TdP) is a ventricular tachycardia associated with prolongation of the corrected QT (QTc) interval, and which may be caused by > 150 widely used drugs. TdP results in catastrophic outcomes, including sudden cardiac death. Older age is a risk factor for drug-induced TdP, possibly due to declining serum progesterone and testosterone concentrations in postmenopausal women and m...

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
https://clinicaltrials.gov/ct2/show/NCT04670666

Aug 5th, 2022 - The purpose of this study is to evaluate the efficacy and safety of Madalena association in the treatment of type 2 diabetes mellitus.

Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus
https://clinicaltrials.gov/ct2/show/NCT04075110

Aug 5th, 2022 - Growing evidences have pointed to the role of 5-lipooxygenase / leukotriene pathway in the pathogenesis of diabesity. Cysteinyl leukotrienes (Cys-LT) are potent inflammatory lipid mediators derived from the 5-lipoxygenase pathway of arachidonic acid metabolism. They act on Cys-LT receptors that are primarily present in the spleen, blood leukocytes, and lung macrophages and are involved in media...

Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension
https://clinicaltrials.gov/ct2/show/NCT04970108

Aug 5th, 2022 - The purpose of this study is to evaluate the efficacy and safety of Egito association in the treatment of type 2 diabetes mellitus and hypertension

Hormonal Regulation of Puberty and Fertility
https://clinicaltrials.gov/ct2/show/NCT01511588

Aug 5th, 2022 - The key initiating factors for reproductive development remain among the great mysteries of pediatric and reproductive endocrinology. The onset of puberty is initiated by pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus. GnRH secretion is fully active during the neonatal period, quiescent throughout most of childhood, and is reactivated at the time of puberty t...